Dr. Reddy's Laboratories Ltd. on Wednesday said it has launched Bortezomib for Injection 3.5 mg/vial, indicated for the treatment of certain types of cancers in adult patients, in the U.S. market.
The company has launched Bortezomib for Injection 3.5 mg/vial, approved by the United States Food and Drug Administration via a new drug application pathway for intravenous use only, Dr. Reddy's Laboratories said in a statement.
"We're pleased to bring this product to market for the customers and patients who will benefit from this cost-efficient alternative in the market place," Dr. Reddy's Laboratories North America Generics Chief Executive Officer Marc Kikuchi said.
This is a great addition to the company's injectable offering in the U.S. market as it continues to augment its portfolio of products in the hospital segment, he added. The company's product is for intravenous use only and is indicated for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, the statement said.
Shares of Dr. Reddy's Laboratories were trading at Rs 2,876.90 per scrip on BSE, up 0.62 percent from its previous close.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
